Optimi Health Launches 1mg and 2mg Microdose Psilocybin


Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Optimi Health Launches Standardized Microdose Psilocybin Products for Research
Vancouver, British Columbia, Canada - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0), a commercial-stage pharmaceutical manufacturer specializing in regulated psychedelic drug products, has announced the production of new standardized microdose psilocybin finished drug products. The company has successfully formulated these products at 1 mg and 2 mg dosages, which are now available to qualified and authorized clinical research organizations.
Key Highlights:
... Read on — Members only
About Optimi Health Corp.
More OPTH News
Health
Business Update

Daily overview of upcoming SPAC and IPO events – from initial announcement to definitive agreement and public listing.

Discover last week’s SPAC and IPO highlights, key trends, and market updates. Stay informed with SpacStar.
















